Diplomat Pharmacy (DPLO) Inactive Financial Report Summaries

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absent, accrual, alleviate, Arizona, Atlanta, avoid, bankruptcy, breach, breaching, breakeven, calendar, career, Carolina, certainty, challenged, Chandler, concurrently, confidence, consummation, core, covenant, creation, default, delay, depressing, difficulty, dispute, distracted, doubt, DSIG, easily, erosion, eventually, facing, failure, foreclose, Georgia, half, history, importantly, imposing, inability, incurrence, insignificant, insolvency, InTouch, lagged, listed, longer, lose, membership, mitigate, mitigating, mitigation, owner, penalty, pertaining, prepay, prevailing, prevent, protection, provisional, recover, refinancing, Regulation, reinvestment, reliant, renegotiate, renegotiating, repay, restructure, restructuring, retroactively, saving, season, small, South, step, stepping, successful, successfully, supplier, Tennessee, thereunder, unanticipated, uncollectible, unrestricted, upcoming, violate, violation, waived, withholding, won

Removed: Circuit, Committee, complementary, County, defendant, demand, demanded, disinterested, enhance, Genesee, investigate, lawsuit, letter, nominal, purported, remedy, response

From filing 10-Q 2019 Q3

Financial report summary

Competition

Cigna

Management Discussion

Net sales for the year ended December 31, 2018 were $5,492,524, a $1,007,294, or 22 percent increase, compared to $4,485,230 for the year ended December 31, 2017. This increase was primarily the result of approximately $788,000 of net sales from our recent acquisitions and approximately $284,000 from the impact of manufacturer price increases.
These increases were partially offset by reimbursement compression and by a decrease in volume primarily in our immunology, hepatitis C, and multiple sclerosis business categories, as well as other lower margin business categories, including human immunodeficiency virus and osteoporosis, versus the prior year.